Partnership creates simplified pathway from early development to commercial launch

Bora Pharmaceuticals Co., Ltd. ("Bora", TWSE: 6472), a global leader in pharmaceutical manufacturing, and Corealis Pharma Inc., a leading early-phase Contract Development Manufacturing Organization (CDMO), have entered into a strategic alliance to provide end-to-end services for oral solid dose (OSD) development and manufacturing. The collaboration will simplify drug development and provide a more scalable pathway to commercialization.

Drug manufacturing has become increasingly complex, requiring specialized partners at every stage of development. Biotech and pharmaceutical innovators will now have access to both Bora's global commercial infrastructure and Corealis' deep expertise in formulation development and clinical-scale manufacturing. The collaboration creates a simple, more efficient route to bring new medicines to patients faster and more reliably.

"This collaboration is about bridging capability and culture," said J.D. Mowery, President of Bora's CDMO division. "By combining Bora's scale-up strength with Corealis' early-phase expertise, and leveraging the reliability of both organizations, we're setting a new standard for CDMO collaboration."

The companies will align project management and quality systems to minimize outsourcing risk for biotech and pharmaceutical companies, integrating from discovery to commercial launch.

"Emerging biotechs often face timeline and flexibility challenges when scaling promising therapies from clinical to commercial lots," said David Leroux-Petersen, CEO of Corealis Pharma. "The alliance with Bora provides our early-stage partners with a clear, fast, seamless, simple path to phase III manufacturing and commercial launch."